Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:6/1/2010

CALGARY, June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

"Obtaining approval to conduct this trial in Belgium will allow us to expand European enrollment in the study and to access leading head and neck specialists," said Dr. Brad Thompson, President and CEO of Oncolytics. "We expect to add Belgian centres over the next quarter as they become available for inclusion in the study."

As previously disclosed, the randomized, two-arm, double-blind, multicentre, two-stage, adaptive Phase 3 trial will assess the intravenous administration of REOLYSIN with the chemotherapy combination of paclitaxel and carboplatin versus the chemotherapy alone in patients with metastatic or recurrent squamous cell carcinoma of the head and neck, or squamous cell cancer of the nasopharynx, who have progressed on or after prior platinum-based chemotherapy. All patients will receive treatment every three weeks (21 day cycles) with paclitaxel and carboplatin and will also receive, on a blinded basis, either intravenous placebo or intravenous REOLYSIN. All dosing takes place in the first five days of each cycle with all patients receiving standard intravenous dos
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
4. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
5. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
6. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
7. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
8. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
9. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... lab of James Tour have brought graphite,s potential as ... reality and created the potential for reprogrammable gate arrays ... logic design. In a paper published in ... postdoctoral associate Alexander Sinitskii show how they,ve used industry-standard ...
... , , CAMBRIDGE, Mass., ... pioneer in the development of next-generation cellulosic ethanol and high-performance specialty ... stock became effective at 5:00 p.m. today. Verenium,s shares will ... "VRNM", with the letter "D" added to the end of the ...
... , SAN DIEGO, Sept. 9 ... Ltd. today announced an exclusive sales agency agreement under which ... presence in Australia. The partnership will initially focus on new ... a strong reputation in the supply of genomics technologies and ...
Cached Biology Technology:Graphitic memory techniques advance at Rice 2Graphitic memory techniques advance at Rice 3Verenium 1:12 Reverse Stock Split Takes Effect 2Verenium 1:12 Reverse Stock Split Takes Effect 3Verenium 1:12 Reverse Stock Split Takes Effect 4SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia 2SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia 3SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia 4
(Date:7/11/2014)... Stem Cell scientists have set a "mouse TRAP" to ... by a recent study published in the Journal ... uses a technique called TRAP to extract cellular and ... Invented by scientists at the Rockefeller Institute for Medical ... to the protein-making machinery, or ribosomes, of the cell ...
(Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
(Date:7/11/2014)... The increased risk of kidney injury related to ... reflects the mass of HES molecules, according to a ... of the International Anesthesia Research Society (IARS). , The ... of HES on cultured human renal proximal tubule cells ... and colleagues of University Hospital Wrzburg, Austria. Other ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... history, are still mightily puzzling the scientists. These plant-eating dinosaurs ... height of 10 meters or more and dominated all other ... to 80 tons, more than any other known land vertebrate. ... giants of the animal kingdom regulated their own body temperature. ...
... corn leads the all-important category of biomass yield. However, focusing ... the current issue of the Proceedings for the National ... looking at the big picture allows other biofuel crops, such ... "We believe our findings have major implications for bioenergy ...
... CAMBRIDGE, MA -- MIT engineers have devised a way ... better than an attogram one millionth of a ... both synthetic nanoparticles and biological components of cells, could ... The system builds on a technology previously developed by ...
Cached Biology News:New research on sauropod gigantism summarized in publicly available collection 2New research on sauropod gigantism summarized in publicly available collection 3More to biofuel production than yield 2Weighing particles at the attogram scale 2Weighing particles at the attogram scale 3Weighing particles at the attogram scale 4
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Request Info...
... Alkaline Phosphatase, Calf Intestinal (CIAP), catalyzes the ... and ribo- and deoxyribonucleoside triphosphates. This enzyme ... of linearized cloning vector DNA by removing ... also be used for the dephosphorylation of ...
100 adhesive strips....
Biology Products: